论文部分内容阅读
目前,大量的65岁以下的成人急性粒细胞白血病患者可以通过冲击诱导化疗而获完全缓解。但是,为延长首次缓解期而进行的维持治疗,包括各种复杂的冲击化疗以及免疗或二者联用,都效果甚微,中数存活期很少有超过18个月的;成人及儿童急性粒细胞白血病的预后普遍不佳。本文作者用Stanozolol(17β-羟基-17α-甲基雄甾烷[3,2-C]吡唑)进行维持缓解治疗,取得了出乎意料的结果。他们根据雄激素对造血细胞作用的知识,把这种弱的雄激素作为一种辅助治疗用于一项开创性的研究,迄今已有8年了。本文报告了对一组获完全
Currently, a large number of adults with acute myeloid leukemia under 65 years of age can be completely relieved by shock-induced chemotherapy. However, maintenance treatment to prolong the initial response period, including various complicated chemotherapy and chemo-therapy, or a combination of both, has little effect and median survival rarely exceeds 18 months; adults and children The prognosis of acute myeloid leukemia is generally poor. The authors achieved sustained relief with Stanozolol (17β-hydroxy-17α-methylandrostane [3,2-c] pyrazole) with unexpected results. They have for eight years been using this weak androgen as a adjuvant therapy in a groundbreaking study based on the androgen’s knowledge of the role of hematopoietic cells. This article reports on a complete set